|*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions. |
The aim being to identify that subset which may better be treated by regimens including DNA cross-linking agents such as platinum, PARP inhibitors and others - rather than perhaps more standard treatment options.
This sub-type of pancreatic cancer (maybe 15%) is related to germline genetic mutations in the 'homologous recombination DNA repair pathway' involving such genes as BRCA1, BRCA2, PALB2, ATM, RAD51, and others.
There is more on our site at: http://pancreatica.org/genetic-testing-for-pancreatic-cancer/
Dale O'Brien, MD
Reply to this message | Return to Main Message List